Cargando…

Delays in Initiating Anti-Cancer Therapy for Early-Stage Breast Cancer—How Slow Can We Go?

Breast cancer is the most commonly diagnosed cancer among women worldwide, and is a leading cause of cancer-related deaths. When diagnosed at an early stage, appropriate and timely treatment results in a high cure rate and better quality of life. Delays in initiating anti-cancer therapy, including s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdel-Razeq, Hikmat, Mansour, Asem, Edaily, Sarah, Dayyat, Abdulmajeed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342560/ https://www.ncbi.nlm.nih.gov/pubmed/37445537 http://dx.doi.org/10.3390/jcm12134502

Ejemplares similares

Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
por: Abdel-Razeq, Hikmat
Publicado: (2021)

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
por: Edaily, Sarah, et al.
Publicado: (2022)

Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2016)

Breast Cancer Care in Jordan
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Trends, Patterns, and Treatment Outcomes of Cancer Among Older Patients in Jordan: A Retrospective Analysis of National Cancer Registry and Institutional Outcome Data
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Metaplastic Breast Carcinoma: Experience of a Tertiary Cancer Center in the Middle East
por: Erjan, Ayah, et al.
Publicado: (2021)

Inferior vena cava filters in cancer patients: to filter or not to filter
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome – a comprehensive cancer center experience
por: Abdel-Razeq, Hikmat N, et al.
Publicado: (2011)

Oncology Medical Training and Practice: Managing Jordan’s Brain Drain Through Brain Train—The King Hussein Cancer Center Experience
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

The application of clinical variables and models to predict pulmonary embolism in cancer patients: a comprehensive single cancer center experience
por: Mansour, Asem, et al.
Publicado: (2013)

Urinary bladder metastasis from primary breast cancer, a rare and challenging diagnosis. A case report and literature review
por: Abdel-Razeq, Rashid, et al.
Publicado: (2022)

COVID-19—Impact on DNR Orders in the Largest Cancer Center in Jordan
por: Shamieh, Omar, et al.
Publicado: (2020)

Rates of Variants of Uncertain Significance Among Patients With Breast Cancer Undergoing Genetic Testing: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Ethical Considerations for Treating Cancer Patients During the SARS-CoV-2 Virus Crisis: To Treat or Not to Treat? A Literature Review and Perspective From a Cancer Center in Low-Middle Income Country
por: Al-Tabba', Amal, et al.
Publicado: (2020)

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Surgical options for patients with early-stage breast cancer and pathogenic germline variants: an oncologist perspectives
por: Abdel-Razeq, Hikmat
Publicado: (2023)

MR imaging features of intracranial primary CNS lymphoma in immune competent patients
por: Mansour, Asem, et al.
Publicado: (2014)

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer
por: Abdel-Razeq, Hikmat
Publicado: (2019)

Golden Jubilee Photos: How slow can they go?
Publicado: (2004)

Anaplastic thyroid cancer: How far can we go?
por: Amaral, Mariana, et al.
Publicado: (2020)

Prognostic Significance of Serum Vitamin D Levels in Egyptian Females with Breast Cancer
por: Abdel-Razeq, Hikmat
Publicado: (2019)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
por: Horani, Malek, et al.
Publicado: (2023)

Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Abdel-Razeq, Hikmat
Publicado: (2016)

Controversies of radiation therapy omission in elderly women with early stage invasive breast cancer
por: Abu-Gheida, Ibrahim, et al.
Publicado: (2020)

Current neoadjuvant treatment options for HER2-positive breast cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Tailoring radicality in early cervical cancer: how far can we go?
por: van der Velden, Jacobus, et al.
Publicado: (2018)

Amenorrhea, fertility preservation, and counseling among young women treated with anthracyclines and taxanes for early-stage breast cancer, a retrospective study
por: Abdel-Razeq, Hikmat N., et al.
Publicado: (2020)

How far can we go in precision with ALR?
por: Blondel, A
Publicado: (1990)

Late presentation and suboptimal treatment of breast cancer among Syrian refugees: a retrospective study
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Dose escalation for locally advanced pancreatic cancer: How high can we go?
por: Colbert, Lauren E., et al.
Publicado: (2018)

Weaning from NIV: how rapidly can we go?
por: Chico, J, et al.
Publicado: (2011)

Digital drainage system: how far can we go?
por: Costa, Altair da Silva, et al.
Publicado: (2014)

TAV-in-TAV and Beyond: How Far Can We Go?
por: Taramasso, Maurizio, et al.
Publicado: (2023)

Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Venous thromboembolism prophylaxis for hospitalized medical patients, current status and strategies to improve
por: Abdel-Razeq, Hikmat
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8eop70mkh9reak045juucc5l86